“…These collaborations can leverage the “know-how” and innovation of academia and the state-of-art facilities, capabilities, and synthetic problems from industry to result in synthetic methods where the product is greater than the sum of its parts. Industrial teams have also helped to advance this field and examples include recent studies on method validation for both medicinal chemistry and process chemistry applications. ,,, Finally, with the fast adoption of photoredox cross-couplings in medicinal chemistry projects, the necessity of large-scale syntheses utilizing this chemistry for drug candidates, or their intermediates, will be inevitable. Some aspects revolving around scalability remain to be addressed, despite the great progress that has been made in this area.…”